Skip to content

The clinical trial to increase the cure rate for advanced cervical cancer with lymph node metastasis

Therapeutic effect of surgical debulking of metastatic lymph node in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial - DEBULK TRIAL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066695
Enrollment
234
Registered
2024-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C56- Malignant neoplasm of ovary

Interventions

Intervention1: CCRT after surgical debulking of bulky LNs or multiple LNs: within 2 weeks after enrollment to end of treatment- CCRT is to be performed after bulky or multiple LN debulking. CCRT cons

Sponsors

Korean Gynecologic Oncology Group
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) Women =20 years and = 70 years of age 1) Newly diagnosed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma 2) When the radiology examinations such as CT, MRI, or PET-CT show the short-axis of the pelvic LN or paraaortic LN under the renal vein is = 2cm, or 3 or more LNs with a short axis = 1 cm 3) When CCRT is planned as a treatment for cervical cancer 4) A patient whose competency is ECOG performance score 0-1 5) A patient which has signed the approved informed consent form for study subjects 6) A patient for which it is determined that surgical debulking is possible for LN metastasis as confirmed by radiological examination

Exclusion criteria

Exclusion criteria: (1) A patient who has been diagnosed with cancer of any organ other than thyroid cancer (excluding stage 0 cancer) within the previous 5 years (2) A patient that is pregnant or plans to become pregnant during the clinical study period (3) A patient with any active infectious disease or incurable severe inflammation. (4) When surgery is not possible due to internal or surgical disease (5) When chemotherapy is impossible due to internal or surgical disease (6) A patient with a history of pelvic radiation therapy (7) A patient with a history of subtotal hysterectomy (7)A patient with a remote metastasis (e.g., lung, supraclavicular lymph node,inguinal lymph node, etc.) other than a pelvic lymph node or paraaortic lymph node metastasis

Design outcomes

Primary

MeasureTime frame
The primary outcome is to check the progression-free survival rateTimepoint: Starting from baseline,(after patient registration) for up to 3 years after the patient is registered.

Secondary

MeasureTime frame
- To compare treatment-related complicationsTimepoint: 1-4 years;- To evaluate the diagnostic accuracy of imaging examination for the diagnosis of bulky LNs or multiple LNsTimepoint: 1-4 years

Countries

India

Contacts

Public ContactDona Chakraborty

KolGOTrg

asima7@yahoo.co.in07044088132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026